Chemical Use & Disclosure

On April 13, 2026, Texas Attorney General Ken Paxton launched a formal investigation into Lululemon over the potential presence of PFAS — per- and polyfluoroalkyl substances, commonly called "forever chemicals" — in its activewear products. The Civil Investigative Demand focuses on whether Lululemon has misled health-conscious consumers by marketing itself as a wellness and sustainability brand while selling products that may contain chemicals linked to endocrine disruption, infertility, and cancer.

Lululemon's response was immediate and specific: the company says it phased out PFAS use entirely by early 2024, where the substances had been used in durable water repellent (DWR) treatments on a small share of outerwear products. The company says it requires all vendors to conduct regular third-party testing for restricted substances including PFAS, and that its products meet or exceed global regulatory standards. Lululemon shares fell about 3% on the announcement, compounding an already difficult stretch for the company that has included weakening sales and leadership changes.

The investigation isn't a verdict. No independent lab results have been made public. But the framing is revealing: the Texas AG is examining not just whether PFAS are present, but whether Lululemon's marketing constituted deceptive misrepresentation — a greenwashing angle. This mirrors an earlier Lululemon class action (still active) that attacked the company's "eco-friendly" marketing claims rather than alleging consumer health harm. The same distinction shows up in the Simply Orange PFAS case: the claim isn't toxic injury, it's undisclosed chemical presence in a product marketed on natural or healthy grounds.

This is also part of a broader enforcement pattern by Paxton. In 2024 he sued 3M and DuPont over PFAS safety misrepresentations in Teflon, Stainmaster, and Scotchgard. The Shein PFAS investigation is ongoing. The Lululemon probe fits a visible strategy of expanding PFAS enforcement from industrial manufacturers to consumer product companies, especially those whose brand identity centers on wellness, sustainability, or clean living.

What This Means for Firms

The operations implication here is about supply chain transparency, not just regulatory compliance. Lululemon's defense rests on vendor testing requirements and restricted substances lists — standard tools in chemical compliance programs. But the investigation signals that those processes may not be enough if a brand's marketing creates expectations that outrun its supply chain's actual chemical transparency. The gap between what firms say about their products and what third-party testing finds is the new litigation frontier.

Connection to My Research

My 2019 M&SOM paper with Kalkanci and Subramanian examined whether hazardous substance rankings — a form of comparative disclosure — actually drove voluntary emissions reductions. The PFAS context is a good test case. The regulatory mechanism here is different (state AG enforcement rather than rankings), but the underlying question is the same: does disclosure pressure change firm behavior, or does it just change firm communication?

Sources

• Texas AG press release, April 13, 2026 — Paxton investigation announcement.
• CBC News / AP, April 13, 2026 — Lululemon response statement.
• ESG Dive, April 2026 — Context on Lululemon's vendor testing protocols and prior Paxton PFAS actions.

The PFAS regulatory environment as of early 2026 is best described as a patchwork — aggressive, fast-moving, and fragmented across state lines. There is no single federal product ban. What exists instead is a growing web of state-level prohibitions, disclosure requirements, and reporting deadlines that vary significantly by product category, state, and timeline.

As of January 2026, new PFAS product prohibitions took effect in Colorado, Connecticut, Illinois, Maine, Minnesota, Vermont, and Washington — covering textiles, cookware, cosmetics, dental floss, cleaning products, children's products, and more. France implemented a national PFAS product ban on January 1 as well. The EU's REACH universal PFAS restriction remains under evaluation, with a final rule expected in spring 2026. Minnesota's Amara's Law — currently the most comprehensive U.S. state statute — will eventually ban intentionally added PFAS in all consumer products by 2032, with a major manufacturer reporting deadline of July 1, 2026.

At the federal level, the EPA's TSCA PFAS Reporting Rule (covering manufacturers and importers who have used PFAS since 2011) had a reporting deadline of January 11, 2026 for most companies. A proposed rule to narrow the definition of "article" and expand de minimis exemptions was under comment at year-end 2025, with a final rule expected in spring 2026. The TSCA rule is notable because it applies to finished products ("articles"), not just raw chemicals — affecting textiles, packaging, electronics, and food service providers far downstream in the supply chain.

The practical challenge for manufacturers: nearly 350 PFAS bills were introduced in 39 states in 2025. The compliance burden is not just chemical reformulation — it's tracking which substances are prohibited in which states for which product categories on which timelines, often with no federal preemption to create consistency. As federal regulators have loosened some PFAS requirements under the current administration, states are explicitly moving to fill the gap.

An Open Question

The research question this raises: in a fragmented regulatory environment where state rules vary significantly, do firms converge on the strictest standard (effectively treating the most restrictive state as the national standard) or do they maintain differentiated product lines? The apparel and consumer products industries seem to be moving toward convergence — primarily because managing PFAS-free and non-PFAS-free supply chains in parallel is operationally costly. But the compliance costs of convergence are also significant. This connects directly to the kind of empirical question I've worked on before: how do firms respond to regulatory variation across jurisdictions?

Sources

• MultiState, January 2026 — Summary of 2025 PFAS state legislation and 2026 trends.
• Morgan Lewis, January 2026 — Legal analysis of new PFAS prohibitions taking effect in 2026.
• Manufacturing Dive, January 2026 — State PFAS laws effective 2026: Illinois, Minnesota, Connecticut, Vermont, Washington, New York.
• Brownstein, November 2025 — Overview of state product bans, federal standards, and legal exposure.
• BCLP, February 2026 — Federal PFAS regulation: 2025 activities and 2026 anticipated actions.

I'm starting this second journal to track chemical use and disclosure developments — an area I've worked on empirically since my 2019 M&SOM paper on hazardous substance rankings (with Kalkanci and Subramanian). The PFAS wave of the last two years has become the most active testing ground for questions I've long been interested in: do disclosure requirements actually change firm behavior, or do they just generate paperwork and litigation?

The structural issue is familiar: chemical hazard information is hard for consumers to access, evaluate, and act on. Regulatory rankings and disclosure requirements try to solve this by making chemical risks visible. But firms can respond to disclosure pressure in multiple ways — actual reformulation, substitution with other chemicals of concern, voluntary phaseouts timed to preempt regulation, or marketing claims that outrun supply chain reality. Each response has different operational and social welfare implications.

PFAS is a particularly interesting case because the regulatory pressure is coming from multiple directions simultaneously: state product bans, federal reporting requirements, state AG enforcement, class action litigation, and greenwashing scrutiny. The cumulative effect on firm behavior — specifically whether it drives genuine supply chain reformulation or strategic communication — is something worth watching carefully week by week.